Related references
Note: Only part of the references are listed.Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells
Huan-Chih Chiu et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Celecoxib Inhibits Interleukin-6/Interleukin-6 Receptor-Induced JAK2/STAT3 Phosphorylation in Human Hepatocellular Carcinoma Cells
Yan Liu et al.
CANCER PREVENTION RESEARCH (2011)
Activation of the Signal Transducer and Activator of Transcription 3 Pathway Up-Regulates Estrogen Receptor-β Expression in Lung Adenocarcinoma Cells
Hao-Chen Wang et al.
MOLECULAR ENDOCRINOLOGY (2011)
The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine
Aws Alshamsan et al.
BIOMATERIALS (2010)
SIGNIFICANCE OF INTERLEUKIN-6 SIGNALING IN THE RESISTANCE OF PHARYNGEAL CANCER TO IRRADIATION AND THE EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR
Chih-Cheng Chen et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas
M. Colomiere et al.
BRITISH JOURNAL OF CANCER (2009)
Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer
Amy Kluge et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling
L. Lin et al.
ONCOGENE (2009)
SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2
Afshin Dowlati et al.
ANTI-CANCER DRUGS (2008)
Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells
Bryan C. Fuchs et al.
CANCER RESEARCH (2008)
The EGFR-STAT3 oncogenic pathway up-regulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition
Arnaud Vigneron et al.
CANCER RESEARCH (2008)
Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-XL enhances antitumor effects in squamous cell carcinoma of the head and neck
Amanda L. Boehm et al.
MOLECULAR PHARMACOLOGY (2008)
Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line
Marzia B. Gariboldi et al.
CANCER LETTERS (2007)
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression
Hui-Wen Lo et al.
CANCER RESEARCH (2007)
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
Melanie B. Thomas et al.
CANCER (2007)
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma
Andrew X. Zhu et al.
CANCER (2007)
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity
Khandaker Siddiquee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib
Christele Desbois-Mouthon et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Regulation of transforming growth factor-β1-induced apoptosis and epithelial-to-mesenchymal transition by protein kinase A and signal transducers and activators of transcription 3
Yanan Yang et al.
CANCER RESEARCH (2006)
Systemic therapy of advanced hepatocellular carcinoma: How hopeful should we be?
Andrew X. Zhu
ONCOLOGIST (2006)
EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization
HW Lo et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer
A Huether et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer
PA Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway
HW Lo et al.
CANCER CELL (2005)
A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells
H Song et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
The stats of cancer - New molecular targets come of age
H Yu et al.
NATURE REVIEWS CANCER (2004)
Cancer genes and the pathways they control
B Vogelstein et al.
NATURE MEDICINE (2004)
Epidermal growth factor receptor inhibition strategies in oncology
PM Harari
ENDOCRINE-RELATED CANCER (2004)
Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis
CM Silva
ONCOGENE (2004)
Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays
A Tannapfel et al.
JOURNAL OF PATHOLOGY (2003)
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer
J Mendelsohn et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells
LX Song et al.
ONCOGENE (2003)
Hepatocyte growth factor, transforming growth factor α, and their receptors as combined markers of prognosis in hepatocellular carcinoma
M Daveau et al.
MOLECULAR CARCINOGENESIS (2003)
Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma
Y Ito et al.
BRITISH JOURNAL OF CANCER (2001)
Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma
CL Campbell et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Share Paper
